Siderophore-fluoroquinolone conjugates containing potential reduction-triggered linkers for drug release: Synthesis and antibacterial activity

BioMetals

Volumn 28, Issue 3, 2015, Pages 541-551

  Ji, Cheng ^a   Miller, Marvin J ^a  

^a UNIVERSITY OF NOTRE DAME   (United States)

Author keywords

Antibiotics; Drug delivery; Drug release; Iron transport; Siderophores; Trojan horse

Indexed keywords

ANTIINFECTIVE AGENT; IRON; QUINOLONE DERIVATIVE; SIDEROPHORE;

BACTERIUM; DRUG EFFECTS; METABOLISM; MICROBIAL SENSITIVITY TEST; SYNTHESIS;

ANTI-BACTERIAL AGENTS; BACTERIA; FLUOROQUINOLONES; IRON; MICROBIAL SENSITIVITY TESTS; SIDEROPHORES;

EID: 84940002596     PISSN: 09660844     EISSN: 15728773     Source Type: Journal    
DOI: 10.1007/s10534-015-9830-3     Document Type: Article

References (33)

1. Boucher HW et al (2009) Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 48:1-12. doi: 10.1086/595011
2. Braun V, Günthner K, Hantke K, Zimmermann L (1983) Intracellular activation of albomycin in Escherichia coli and Salmonella typhimurium. J Bacteriol 156:308-315
3. Braun V, Pramanik A, Gwinner T, Koberle M, Bohn E (2009) Sideromycins: tools and antibiotics. Biometals 22:3-13. doi: 10.1007/s10534-008-9199-7
4. Diarra MS et al (1996) Species selectivity of new siderophore-drug conjugates that use specific iron uptake for entry into bacteria. Antimicrob Agents Chemother 40:2610-2617
5. Fernandez L, Hancock REW (2012) Adaptive and mutational resistance: role of porins and efflux pumps in drug resistance. Clin Microbiol Rev 25:661-681. doi: 10.1128/cmr.00043-12
6. Ghosh A, Ghosh M, Niu C, Malouin F, Möllmann U, Miller MJ (1996) Iron transport-mediated drug delivery using mixed-ligand siderophore-β-lactam conjugates. Chem Biol 3:1011-1019. doi: 10.1016/s1074-5521(96)90167-2
7. Harrington JM, Crumbliss AL (2009) The redox hypothesis in siderophore-mediated iron uptake. Biometals 22:679-689. doi: 10.1007/s10534-009-9233-4
8. Hennard C, Truong QC, Desnottes JF, Paris JM, Moreau NJ, Abdallah MA (2001) Synthesis and activities of pyoverdin-quinolone adducts: a prospective approach to a specific therapy against Pseudomonas aeruginosa. J Med Chem 44:2139-2151. doi: 10.1021/jm990508g
9. Ji C, Miller MJ (2012) Chemical syntheses and in vitro antibacterial activity of two desferrioxamine B-ciprofloxacin conjugates with potential esterase and phosphatase triggered drug release linkers. Bioorg Med Chem 20:3828-3836. doi: 10.1016/j.bmc.2012.04.034
10. Ji C, Juárez-Hernández RE, Miller MJ (2012a) Exploiting bacterial iron acquisition: siderophore conjugates. Future Med Chem 4:297-313. doi: 10.4155/fmc.11.191
11. Ji C, Miller PA, Miller MJ (2012b) Iron transport-mediated drug delivery: practical syntheses and in vitro antibacterial studies of tris-catecholate siderophore-aminopenicillin conjugates reveals selectively potent antipseudomonal activity. J Am Chem Soc 134:9898-9901. doi: 10.1021/ja303446w
12. Levine MN, Raines RT (2012) Trimethyl lock: a trigger for molecular release in chemistry, biology, and pharmacology. Chem Sci 3:2412-2420. doi: 10.1039/c2sc20536j
13. Levy SB, Marshall B (2004) Antibacterial resistance worldwide: causes, challenges and responses. Nat Med 10:S122-S129. doi: 10.1038/nm1145
14. Mendoza MF, Hollabaugh NM, Hettiarachchi SU, McCarley RL (2012) Human NAD(P)H:quinone oxidoreductase Type I (hNQO1) activation of quinone propionic acid trigger groups. Biochemistry 51:8014-8026. doi: 10.1021/bi300760u
15. Miethke M, Marahiel MA (2007) Siderophore-based iron acquisition and pathogen control. Microbiol Mol Biol Rev 71:413-451. doi: 10.1128/mmbr.00012-07
16. Mislin GLA, Schalk IJ (2014) Siderophore-dependent iron uptake systems as gates for antibiotic Trojan horse strategies against Pseudomonas aeruginosa. Metallomics 6:408-420. doi: 10.1039/c3mt00359k
17. Mitscher LA (2005) Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem Rev 105:559-592. doi: 10.1021/cr030101q
18. Möllmann U, Heinisch L, Bauernfeind A, Köhler T, Ankel-Fuchs D (2009) Siderophores as drug delivery agents: application of the "Trojan Horse" strategy. Biometals 22:615-624. doi: 10.1007/s10534-009-9219-2
19. Müller G, Raymond KN (1984) Specificity and mechanism of ferrioxamine-mediated iron transport in Streptomyces pilosus. J Bacteriol 160:304-312
20. Noël S, Gasser V, Pesset B, Hoegy F, Rognan D, Schalk IJ, Mislin GLA (2011) Synthesis and biological properties of conjugates between fluoroquinolones and a N3″-functionalized pyochelin. Org Biomol Chem 9:8288-8300. doi: 10.1039/c1ob06250f
21. Ong W, Yang Y, Cruciano AC, McCarley RL (2008) Redox-triggered contents release from liposomes. J Am Chem Soc 130:14739-14744. doi: 10.1021/ja8050469
22. Page MGP (2013) Siderophore conjugates. Ann NY Acad Sci 1277:115-126. doi: 10.1111/nyas.12024
23. Pages JM, James CE, Winterhalter M (2008) The porin and the permeating antibiotic: a selective diffusion barrier in Gram-negative bacteria. Nat Rev Microbiol 6:893-903. doi: 10.1038/nrmicro1994
24. Projan SJ (2003) Why is big pharma getting out of antibacterial drug discovery? Curr Opin Microbiol 6:427-430. doi: 10.1016/j.mib.2003.08.003
25. Rivault F, Liebert C, Burger A, Hoegy F, Abdallah MA, Schalk IJ, Mislin GLA (2007) Synthesis of pyochelin-norfloxacin conjugates. Bioorg Med Chem Lett 17:640-644. doi: 10.1016/j.bmcl.2006.11.005
26. Roosenberg JM, Miller MJ (2000) Total synthesis of the siderophore danoxamine. J Org Chem 65:4833-4838. doi: 10.1021/jo000050m
27. Schröder I, Johnson E, de Vries S (2003) Microbial ferric iron reductases. FEMS Microbiol Rev 27:427-447. doi: 10.1016/s0168-6445(03)00043-3
28. Spellberg B et al (2008) The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 46:155-164. doi: 10.1086/524891
29. Vértesy L, Aretz W, Fehlhaber HW, Kogler H (1995) Salmycin A-D, antibiotics from Streptomyces violaceus, DSM 8286, having a siderophore aminoglycoside structure. Helv Chim Acta 78:46-60. doi: 10.1002/hlca.19950780105
30. Wencewicz TA, Miller MJ (2013) Biscatecholate-monohydroxamate mixed ligand siderophore-carbacephalosporin conjugates are selective sideromycin antibiotics that target Acinetobacter baumannii. J Med Chem 56:4044-4052. doi: 10.1021/jm400265k
31. Wencewicz TA, Möllmann U, Long TE, Miller MJ (2009) Is drug release necessary for antimicrobial activity of siderophore-drug conjugates? Syntheses and biological studies of the naturally occurring salmycin "Trojan Horse" antibiotics and synthetic desferridanoxamine-antibiotic conjugates. Biometals 22:633-648. doi: 10.1007/s10534-009-9218-3
32. Wencewicz TA, Long TE, Möllmann U, Miller MJ (2013) Trihydroxamate siderophore-fluoroquinolone conjugates are selective sideromycin antibiotics that target Staphylococcus aureus. Bioconjug Chem 24:473-486. doi: 10.1021/bc300610f
33. Zheng T, Nolan EM (2014) Enterobactin-mediated delivery of β-lactam antibiotics enhances antibacterial activity against pathogenic Escherichia coli. J Am Chem Soc 136:9677-9691. doi: 10.1021/ja503911p